Paradigm Capital analyst Scott McAuley likes what he sees in clinical stage medical device company Spectral Medical, saying in a Wednesday update that the stock is clearly undervalued at current levels.
It’s still a “Hold” on US cannabis name Cresco Labs, according to Echelon Capital Markets analyst Andrew Semple, who reviewed Cresco’s latest quarterly results in a Wednesday report.
Raymond James analyst Rahul Sarugaser is sticking with a Market Perform rating on Arch Biopartners, saying in a Tuesday update that caution is the wise approach.
Roth Capital Partners analyst Eric Handler reviewed the latest results and coming attractions from the cinema market on Monday and reiterated a “Buy” rating on IMAX.
The stock has already had a tremendous 2023, but investors can expect even more upside from Kits Eyecare, according to Beacon Securities analyst Doug Cooper, who provided an update to clients on Monday.